Efficacy and safety of abatacept in active primary Sjögren's syndrome: Results of a phase III, randomised, placebo-controlled trial

Alan N. Baer, Jacques Eric Gottenberg, E. William St Clair, Takayuki Sumida, Tsutomu Takeuchi, Raphaèle Seror, Gary Foulks, Marleen Nys, Sumanta Mukherjee, Robert Wong, Neelanjana Ray, Hendrika Bootsma

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


Objectives To evaluate efficacy and safety of abatacept in adults with active primary Sjögren's syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial. Methods Eligible patients (moderate-to-severe pSS [2016 ACR/European League Against Rheumatism (EULAR) criteria], EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI] ≥5, anti-SS-related antigen A/anti-Ro antibody positive) received weekly subcutaneous abatacept 125 mg or placebo for 169 days followed by an open-label extension to day 365. Primary endpoint was mean change from baseline in ESSDAI at day 169. Key secondary endpoints were mean change from baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and stimulated whole salivary flow (SWSF) at day 169. Other secondary clinical endpoints included glandular functions and patient-reported outcomes. Selected biomarkers and immune cell phenotypes were examined. Safety was monitored. Results Of 187 patients randomised, 168 completed double-blind period and 165 continued into open-label period. Mean (SD) baseline ESSDAI and ESSPRI total scores were 9.4 (4.3) and 6.5 (2.0), respectively. Statistical significance was not reached for primary (ESSDAI -3.2 abatacept vs -3.7 placebo, p=0.442) or key secondary endpoints (ESSPRI, p=0.337; SWSF, p=0.584). No clinical benefit of abatacept over placebo at day 169 was seen with other clinical and PRO endpoints. Relative to baseline, abatacept was associated with significant differences vs placebo in some disease-relevant biomarkers (including IgG, IgA, IgM-rheumatoid factor) and pathogenic cell subpopulations (post hoc analyses). No new safety signals were identified. Conclusions Abatacept treatment did not result in significant clinical efficacy compared with placebo in patients with moderate-to-severe pSS, despite evidence of biological activity.

Original languageEnglish
Pages (from-to)339-348
Number of pages10
JournalAnnals of the rheumatic diseases
Issue number3
Publication statusPublished - 2021 Mar 1


  • Sjogren's syndrome
  • autoimmune diseases
  • therapeutics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'Efficacy and safety of abatacept in active primary Sjögren's syndrome: Results of a phase III, randomised, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this